A balance between innovation and biosafety.
作者信息
Perlman Stanley
机构信息
Department of Microbiology and Immunology, University of Iowa, Iowa City, IA 52242.
出版信息
Proc Natl Acad Sci U S A. 2024 Jul 16;121(29):e2410451121. doi: 10.1073/pnas.2410451121. Epub 2024 Jul 8.
Abstract
摘要
相似文献
1
A balance between innovation and biosafety.
Proc Natl Acad Sci U S A. 2024 Jul 16;121(29):e2410451121. doi: 10.1073/pnas.2410451121. Epub 2024 Jul 8.
2
Preparedness to face the COVID-19 pandemic - is India missing the mark?
J Glob Health. 2020 Dec;10(2):020338. doi: 10.7189/jogh.10.020338.
3
India's Bhilwara COVID-19 containment policy response: Lessons for public health policy makers globally.
J Glob Health. 2020 Dec;10(2):020325. doi: 10.7189/jogh.10.020325.
4
Dermatopathology practice in the era of COVID-19.
Arch Dermatol Res. 2021 Dec;313(10):811-813. doi: 10.1007/s00403-020-02183-x. Epub 2021 Feb 9.
5
Biosafety Professionals: A Role in the Pandemic Response Team.
Health Secur. 2021 Jul-Aug;19(4):454-458. doi: 10.1089/HS.2021.0015.
6
A Cytometrist's Guide to Coordinating and Performing Effective COVID-19 Research.
Cytometry A. 2021 Jan;99(1):11-18. doi: 10.1002/cyto.a.24210. Epub 2020 Sep 8.
7
Masks for at-risk population: nursing promoting biosafety in pandemic times.
Rev Gaucha Enferm. 2021 May 19;42(spe):e20200276. doi: 10.1590/1983-1447.2021.20200276. eCollection 2021.
8
Aerosol-Containment Device for Prevention of Aerosol Dispersion During Nebulization in COVID-19 Patients.
J Cardiothorac Vasc Anesth. 2021 Mar;35(3):967-969. doi: 10.1053/j.jvca.2020.06.066. Epub 2020 Jun 23.
9
Biosafety and Biohazards: Understanding Biosafety Levels and Meeting Safety Requirements of a Biobank.
Methods Mol Biol. 2019;1897:213-225. doi: 10.1007/978-1-4939-8935-5_19.
10
Biosafety in the preparation and processing of cytology specimens with potential coronavirus (COVID-19) infection: Perspectives from Taiwan.
Cancer Cytopathol. 2020 May;128(5):309-316. doi: 10.1002/cncy.22280. Epub 2020 Apr 7.
引用本文的文献
1
Reply to Masters: Recombinant coronavirus balances biosafety and benefit.
Proc Natl Acad Sci U S A. 2024 Oct 29;121(44):e2416109121. doi: 10.1073/pnas.2416109121. Epub 2024 Oct 21.
本文引用的文献
1
Recombinant OC43 SARS-CoV-2 spike replacement virus: An improved BSL-2 proxy virus for SARS-CoV-2 neutralization assays.
Proc Natl Acad Sci U S A. 2024 Jul 16;121(29):e2310421121. doi: 10.1073/pnas.2310421121. Epub 2024 Jul 8.
2
Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques.
Nature. 2024 Feb;626(7998):385-391. doi: 10.1038/s41586-023-06951-3. Epub 2023 Dec 14.
3
Reverse genetic systems of SARS-CoV-2 for antiviral research.
Antiviral Res. 2023 Feb;210:105486. doi: 10.1016/j.antiviral.2022.105486. Epub 2022 Dec 22.
4
Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses.
Science. 2022 Nov 25;378(6622):eabo2523. doi: 10.1126/science.abo2523.
5
Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19.
Nature. 2022 May;605(7908):146-151. doi: 10.1038/s41586-022-04630-3. Epub 2022 Mar 21.
6
Establishment of a reverse genetics system for SARS-CoV-2 using circular polymerase extension reaction.
Cell Rep. 2021 Apr 20;35(3):109014. doi: 10.1016/j.celrep.2021.109014. Epub 2021 Apr 1.
7
Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection.
J Exp Med. 2021 May 3;218(5). doi: 10.1084/jem.20202617.
8
SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function.
Nat Immunol. 2020 Nov;21(11):1327-1335. doi: 10.1038/s41590-020-0778-2. Epub 2020 Aug 24.
9
More than just a common cold: Endemic coronaviruses OC43, HKU1, NL63, and 229E associated with severe acute respiratory infection and fatality cases among healthy adults.
J Med Virol. 2021 Feb;93(2):1002-1007. doi: 10.1002/jmv.26362. Epub 2020 Aug 2.
10
Circulation of genetically distinct contemporary human coronavirus OC43 strains.
Virology. 2005 Jun 20;337(1):85-92. doi: 10.1016/j.virol.2005.04.010.
Zotero 插件